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Background: Infections remain a serious compLi- 
cation in patients undergoing aLLogeneic stem ceLL 
TranspLantation. We sought to determine spectrum 
of infections in CBST recipients at our institution. 
Methods: This retrospective analysis was per- 
formed after obtaining approval from Institutional 
Review Board. Records of aLL 97 recipients of 
CBST were evaluated using a standardized data 
retrieval mechanism. ALL values are presented as 
median+s.d. 
Results: Among 59 pediatric and 38 adult pa- 
tients age was 74-5 years and 334-12 years, respec- 
tively. Ninety-four (97%) of 97 patients had under- 
Lying hematologic malignancy, acute Lymphocytic 
Leukemia was common (40 [43%] of 94) foLLowed 
by acute myeLogenous Leukemia (26 [28%] of 94). 
Myetoabtative conditioning regimen was given in 
40 (40%) patients; engraftment occurred 244-9 days 
foLLowing transplant. In 20 patients (21%) failure 
was either due to primary non-engraftment or 
refractory Leukemia. Seventy percent had graft- 
versus-host-diseases (GVHD), median time from 
transplantation and diagnosis of GVHD was 184-39 
post-CBSCT days. The infections complications are 
shown in the table below. The overaLL mortality 
was 66% foLLowin g CBST (median 1474-214 days and 
range, 10 to 993 days), in 20 (31%) of 64 patients 
who died, death was associated with an infection- 
related complication. 
Conclusions: InterestingLy, nearly a quarter of sys- 
temic bacterial and viral infections were noted 
after 100 days post-transpLantation. Whereas, most 
systemic funga[ infections in these severely im- 
munosuppressed patients including those with 
GVHD occurred within 30 days of receiving 
unreLated-donor CBST. 
Episode type Days Fo[[owin 8 CBSCT 
0-30 31-100 100 Overall 
54 (19) 19 (7) 21 (7) 94 (33) 
31 (11) 35 (12) 25 (9) 91 (32) 
12 (4) 11 (4) I (0.5) 24 (9) 
26 (9) 8 (3) 5 (2) 39 (14) 
8 (3) 1 (0.5) 1 (0.5) 10 (4) 
0 (0) 3 (1) 1 (0.5) 4 (2) 
8 (3) 5 (2) 6 (2) 19 (7) 
139 (49) 82 (29) 60 (21) 281 (100) 
aCDl: CLinicaL document infections. 
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Background: Bone marrow transplantation (BMT) 
is a treatment of choice for various malignant and 
inherited disorders. UnfortunateLy, this therapy is 
plagued by numerous pulmonary complications. 
Infections by the Gram-negative bacteria Pseu- 
domonas aeruginosa have emerged as a Leading 
cause of nosocomia[ pneumonia post-BMT. We have 
previously shown that mice receiving a syngeneic 
BMT are more susceptible to P. aeruginosa infec- 
tions in vivo. We have shown that the increased 
susceptibility of BMT mice is due to defective 
phagocytosis by the aLveoLar macrophages (AMs) 
and an inability of these ceLLs to produce activating 
cytokines, such as TNF-aLpha. Previous work has 
shown that eicosanoids, ceLL-secreted Lipid medi- 
ators, have an important role in the regulation of 
innate immunity. InterestingLy, BMT patients have 
increased LeveLs of circulating prostagLandin E2 
(PGE2), a negative regulator of the innate immune 
system, in their plasma for weeks to months post- 
transplant. 
Objective: Our hypothesis is that altered synthesis 
of eicosanoids contributes to immunosuppression 
post-BMT. 
